Proefschrift

Ryan, C., Smith, M., De Bono, J., Molina, A., Logothetis, C., De Souza, P., Fizazi, K., Mainwaring, P., Piulats, J., and Ng, S. (2013). Abiraterone in metastatic prostate cancer without previous chemotherapy. New England Journal of Medicine , 368(2):138–148. 49 Ryan, C., Smith, M., Fizazi, K., Saad, F., Mulders, P., Sternberg, C., Miller, K., Logothetis, C., Shore, N., Small, E., et al. (2015). Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology , 16(2):152–160. 54 Ryan, C., Smith, M., Fong, L., Rosenberg, J., Kantoff, P., Raynaud, F., Martins, V., Lee, G., Kheoh, T., Kim, J., et al. (2010). Phase I clinical trial of the cyp17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. Journal of Clinical Oncology , 28(9):1481–1488. 49 Sandrock, C. (2020). Plot ternary diagrams in Matlab . 96 Sasaki, T. and Sugimura, Y. (2018). The importance of time to prostate-specific antigen (PSA) nadir after primary androgen deprivation therapy in hormone-na¨ıve prostate cancer patients. Journal of Clinical Medicine , 7(12):565. 112 Scher, H., Halabi, S., Tannock, I., Morris, M., Sternberg, C., Carducci, M., Eisenberger, M., Higano, C., Bubley, G., Dreicer, R., et al. (2008). Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology , 26(7):1148–1159. 55 Scher, H., Heller, G., Molina, A., Attard, G., Danila, D., Jia, X., Peng, W., Sandhu, S., Olmos, D., Riisnaes, R., et al. (2015). Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. Journal of Clinical Oncology , 33(12):1348–1355. 98 Schipper, H., Goh, C., and Wang, T. (1995). Shifting the cancer paradigm: must we kill to cure? Journal of Clinical Oncology , 13(4):801–807. 9 Schoener, T. (1983). Field experiments on interspecific competition. The American Naturalist , 122(2):240–285. 31 Schultz, M., Parzinger, H., Posdnjakov, D., Chikisheva, T., and Schmidt-Schultz, T. (2007). Oldest known case of metastasizing prostate carcinoma diagnosed in the skeleton of a 2,700-year-old Scythian king from Arzhan (Siberia, Russia). International Journal of Cancer , 121(12):2591–2595. 4 184